Multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	B-Cell
cells	I-Cell
modelled	O
by	O
co	O
-	O
expression	O
of	O
telomerase	O
reverse	O
transcriptase	O
,	O
SV40	O
T	O
antigen	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

We	O
have	O
modelled	O
multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	B-Cell
cells	I-Cell
(	O
ECs	B-Cell
)	O
by	O
overexpressing	O
the	O
catalytic	O
subunit	O
of	O
human	O
telomerase	O
(	O
hTERT	O
)	O
,	O
together	O
with	O
SV40	O
T	O
antigen	O
(	O
SV40T	O
)	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

Transfection	O
with	O
hTERT	O
alone	O
,	O
led	O
to	O
the	O
immortalization	O
of	O
two	O
out	O
of	O
three	O
cultures	B-Cell
of	O
bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
ECs	I-Cell
(	O
BMECs	B-Cell
)	O
.	O

One	O
hTERT	O
transduced	O
BMEC	B-Cell
culture	I-Cell
underwent	O
a	O
long	O
proliferative	O
lag	O
before	O
resuming	O
proliferation	O
.	O

BMECs	B-Cell
transfected	O
with	O
hTERT	O
alone	O
were	O
functionally	O
and	O
phenotypically	O
normal	O
.	O

BMECs	B-Cell
transfected	O
with	O
SV40T	O
(	O
BMSVTs	B-Cell
)	O
had	O
an	O
extended	O
lifespan	O
,	O
but	O
eventually	O
succumbed	O
to	O
crisis	O
.	O

BMSVTs	B-Cell
exhibited	O
a	O
partially	O
transformed	O
phenotype	O
,	O
demonstrating	O
growth	O
factor	O
independence	O
,	O
altered	O
antigen	O
expression	O
and	O
forming	O
tiny	O
,	O
infrequent	O
colonies	B-Cell
in	O
vitro	O
.	O

Transduction	O
of	O
BMSVTs	B-Cell
with	O
hTERT	O
resulted	O
in	O
immortalization	O
of	O
4	O
out	O
of	O
4	O
cultures	B-Cell
.	O

BMSVTs	B-Cell
immortalized	O
with	O
hTERT	O
formed	O
large	O
colonies	B-Cell
in	O
vitro	O
and	O
small	O
transient	O
tumours	B-Cancer
in	O
vivo	O
.	O

BMECs	B-Cell
co	O
-	O
expressing	O
SV40T	O
,	O
hTERT	O
and	O
N	O
-	O
ras	O
exhibited	O
an	O
overtly	O
transformed	O
phenotype	O
;	O
forming	O
very	O
large	O
colonies	B-Cell
with	O
an	O
altered	O
morphology	O
and	O
generating	O
rapidly	O
growing	O
tumours	B-Cancer
in	O
vivo	O
.	O

These	O
investigations	O
demonstrate	O
transformation	O
of	O
human	O
ECs	B-Cell
to	O
an	O
overtly	O
malignant	O
phenotype	O
.	O

This	O
model	O
will	O
be	O
useful	O
for	O
understanding	O
mechanisms	O
underlying	O
vascular	B-Cancer
and	O
angiogenic	B-Cancer
neoplasias	I-Cancer
,	O
as	O
well	O
as	O
for	O
testing	O
drugs	O
designed	O
to	O
curtail	O
aberrant	O
EC	B-Cell
growth	O
.	O

